Rezolute, Inc. RZLT
We take great care to ensure that the data presented and summarized in this overview for Rezolute, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RZLT
View all-
Federated Hermes, Inc. Pittsburgh, PA14MShares$87 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.02MShares$24.9 Million0.0% of portfolio
-
Blackstone Inc New York, NY3.56MShares$22.1 Million0.08% of portfolio
-
Ubs Group Ag3.04MShares$18.8 Million0.0% of portfolio
-
Great Point Partners LLC Greenwich, CT3.03MShares$18.8 Million11.22% of portfolio
-
Marshall Wace, LLP London, X02.89MShares$17.9 Million0.02% of portfolio
-
Mangrove Partners New York, NY2.3MShares$14.2 Million1.48% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.29MShares$14.2 Million0.45% of portfolio
-
Affinity Asset Advisors, LLC New York, NY2.2MShares$13.6 Million1.65% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.11MShares$13.1 Million1.99% of portfolio
Latest Institutional Activity in RZLT
Top Purchases
Top Sells
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Insider Transactions at RZLT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2025
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
10,549
+7.41%
|
$52,745
$5.04 P/Share
|
|
Jun 25
2025
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+13.89%
|
$10,000
$4.38 P/Share
|
|
Jun 24
2025
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
5,000
+1.83%
|
$20,000
$4.05 P/Share
|
|
Jun 13
2025
|
Young Jin Kim |
BUY
Open market or private purchase
|
Indirect |
1,230,769
+12.75%
|
$3,692,307
$3.25 P/Share
|
|
Jun 13
2025
|
Nerissa Kreher |
BUY
Open market or private purchase
|
Direct |
3,076
+7.57%
|
$9,228
$3.25 P/Share
|
|
Jun 10
2025
|
Nerissa Kreher |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+20.69%
|
-
|
|
Jun 10
2025
|
Gil M Labrucherie |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+20.69%
|
-
|
|
Jun 10
2025
|
Wladimir Hogenhuis |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+8.82%
|
-
|
|
Jun 10
2025
|
Daron Evans CFO |
BUY
Grant, award, or other acquisition
|
Direct |
26,000
+8.97%
|
-
|
|
Jun 10
2025
|
Young Jin Kim |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+5.66%
|
-
|
|
Jun 10
2025
|
Philippe Fauchet |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+20.69%
|
-
|
|
Jun 10
2025
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,000
+14.18%
|
-
|
|
Jun 10
2025
|
Nevan C Elam CEO |
BUY
Grant, award, or other acquisition
|
Direct |
68,000
+18.88%
|
-
|
|
Mar 31
2025
|
Wladimir Hogenhuis |
BUY
Open market or private purchase
|
Direct |
6,758
+7.44%
|
$13,516
$2.92 P/Share
|
|
Mar 27
2025
|
Nevan C Elam CEO |
BUY
Open market or private purchase
|
Direct |
12,302
+5.2%
|
$24,604
$2.85 P/Share
|
|
Mar 26
2025
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
10,000
+30.3%
|
$20,000
$2.88 P/Share
|
|
Mar 26
2025
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
10,000
+4.03%
|
$20,000
$2.89 P/Share
|
|
Feb 18
2025
|
Wladimir Hogenhuis |
BUY
Open market or private purchase
|
Direct |
10,000
+11.46%
|
$40,000
$4.7 P/Share
|
|
Feb 16
2025
|
Wladimir Hogenhuis |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+27.49%
|
-
|
|
Feb 16
2025
|
Gil M Labrucherie |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 651K shares |
|---|---|
| Open market or private purchase | 1.32M shares |